87 related articles for article (PubMed ID: 26526)
21. Phase I trial and pharmacokinetics of a daily x 5 schedule of 3-deazauridine.
Creaven PJ; Priore RL; Mittelman A; Bruno S; Henderson ES; Rustum YM; Solomon JK
Cancer Treat Rep; 1982 Jan; 66(1):81-4. PubMed ID: 7053271
[TBL] [Abstract][Full Text] [Related]
22. 3-Deazauridine (NSC 126849): an interesting modulator of biochemical response.
Moriconi WJ; Slavik M; Taylor S
Invest New Drugs; 1986; 4(1):67-84. PubMed ID: 2422137
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
Moyer JD; Karle JM; Malinowski N; Marquez VE; Salam MA; Malspeis L; Cysyk RL
Mol Pharmacol; 1985 Nov; 28(5):454-60. PubMed ID: 2997596
[TBL] [Abstract][Full Text] [Related]
24. Phase I--II study of 3-deazauridine in adults with acute leukemia.
Yap BS; McCredie KB; Keating MJ; Bodey GP; Freireich EJ
Cancer Treat Rep; 1981; 65(5-6):521-4. PubMed ID: 7237473
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological activity of 4-beta-Iribofuranosyl-1,3-dihydroxybenzene ("1,3-dideazauridine").
Sharma RA; Bobek M; Bloch A
J Med Chem; 1975 May; 18(5):473-6. PubMed ID: 168382
[TBL] [Abstract][Full Text] [Related]
26. Sample preparation and estimation of plasma concentration of 3-deazauridine by high-performance liquid chromatography.
Lin KT; Momparler RL; Rivard GE
Ther Drug Monit; 1983; 5(4):491-6. PubMed ID: 6659019
[TBL] [Abstract][Full Text] [Related]
27. Nucleic acid related compounds. 17.3-Deazuridine. Stannous chloride catalysis of cis-diol vs. phenolic base methylation with diazomethane.
Robins MJ; Lee AS
J Med Chem; 1975 Nov; 18(11):1070-4. PubMed ID: 809580
[TBL] [Abstract][Full Text] [Related]
28. Quantitative determination of nucleosides and their phosphate esters--1. The acidic nucleosides, 3-deazauridine and 6-azauridine.
Welch AD; Nemec J; Panahi J
Int J Biochem; 1984; 16(6):587-91. PubMed ID: 6205910
[TBL] [Abstract][Full Text] [Related]
29. Synthetic studies on 3-deazauridine derivatives.
Kaneko M; Robins MJ
Nucleic Acids Symp Ser; 1982; (11):49-52. PubMed ID: 7183971
[No Abstract] [Full Text] [Related]
30. Biochemical and pharmacological effects of the fermentation-derived antitumor agent, (alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125).
Neil GL; Berger AE; McPartland RP; Grindey GB; Bloch A
Cancer Res; 1979 Mar; 39(3):852-6. PubMed ID: 427775
[No Abstract] [Full Text] [Related]
31. Phase II study of 3-deazauridine in advanced colorectal adenocarcinoma.
Bruno S; Creaven PJ; Ledesma E; Poster D; Yoon J; Mittelman A
Am J Clin Oncol; 1982 Feb; 5(1):69-71. PubMed ID: 7081140
[TBL] [Abstract][Full Text] [Related]
32. Homogeneous uridine kinase from Ehrlich ascites tumor: substrate specificity and inhibition by bisubstrate analogs.
Cheng N; Payne RC; Kemp WE; Traut TW
Mol Pharmacol; 1986 Aug; 30(2):159-63. PubMed ID: 3016499
[TBL] [Abstract][Full Text] [Related]
33. The structure of nucleosides in relation to their biological and and biochemical activity: a summary.
Bloch A
Ann N Y Acad Sci; 1975 Aug; 255():576-96. PubMed ID: 53023
[No Abstract] [Full Text] [Related]
34. Synthesis of diazaphenoxathiin nucleosides from 3-deazauridine and their chemical properties.
Kaneko M; Kimura M; Murofushi Y; Robins MJ
Nucleic Acids Symp Ser; 1983; (12):13-6. PubMed ID: 6664846
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of 3-deazauridine in the treatment of adults with solid tumors.
Stewart DJ; McCredie KD; Barlogie B; Valdivieso M; Benjamin RS; Burgess MA; Bodey GP
Cancer Treat Rep; 1980; 64(12):1295-9. PubMed ID: 7471119
[TBL] [Abstract][Full Text] [Related]
36. Enzyme pattern-directed chemotherapy: synergistic interaction of 3-deazauridine with D-galactosamine.
Jackson RC; Williams JC; Weber G
Cancer Treat Rep; 1976 Jul; 60(7):835-43. PubMed ID: 188552
[TBL] [Abstract][Full Text] [Related]
37. Cyclopentenyluridine and cyclopentenylcytidine analogues as inhibitors of uridine-cytidine kinase.
Lim MI; Moyer JD; Cysyk RI; Marquez VE
J Med Chem; 1984 Dec; 27(12):1536-8. PubMed ID: 6094806
[No Abstract] [Full Text] [Related]
38. Prevention by testosterone of the intestinal toxicity caused by the antitumor agent 3-deazauridine.
Bloch A; Dutschman G; Grindey G; Simpson CL
Cancer Res; 1974 Jun; 34(6):1299-303. PubMed ID: 4826501
[No Abstract] [Full Text] [Related]
39. Cytotoxic and biochemical effects of thymidine and 3-deazauridine on human tumor cells.
Lockshin A; Mendoza JT; Giovanella BC; Stehlin JS
Cancer Res; 1984 Jun; 44(6):2534-9. PubMed ID: 6722792
[TBL] [Abstract][Full Text] [Related]
40. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in neoplastic and normal cells.
Lauzon GJ; Paterson AR; Belch AW
Cancer Res; 1978 Jun; 38(6):1730-3. PubMed ID: 274175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
